-
1
-
-
79953805710
-
An evidence-based systematic review on medical therapies for inflammatory bowel disease
-
quiz S26
-
Talley NJ, Abreu MT, Achkar JP, et al. An evidence-based systematic review on medical therapies for inflammatory bowel disease. Am J Gastroenterol 2011;106(Suppl 1):S2 -25; quiz S26.
-
(2011)
Am J Gastroenterol
, vol.106
, pp. S2-S25
-
-
Talley, N.J.1
Abreu, M.T.2
Achkar, J.P.3
-
2
-
-
34447102570
-
American gastroenterological association consensus development conference on the use of biologics in the treatment of inflammatory bowel disease, June 21-23, 2006
-
Clark M, Colombel JF, Feagan BC, et al. American gastroenterological association consensus development conference on the use of biologics in the treatment of inflammatory bowel disease, June 21-23, 2006. Gastroenterology 2007;133:312-39.
-
(2007)
Gastroenterology
, vol.133
, pp. 312-339
-
-
Clark, M.1
Colombel, J.F.2
Feagan, B.C.3
-
3
-
-
75149161836
-
The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Current management
-
Dignass A, Van Assche G, Lindsay JO, et al. The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: current management. J Crohns Colitis 2010;4:28-62.
-
(2010)
J Crohns Colitis
, vol.4
, pp. 28-62
-
-
Dignass, A.1
Van Assche, G.2
Lindsay, J.O.3
-
4
-
-
38749095183
-
European evidence-based consensus on the management of ulcerative colitis: Current management
-
Travis SP, Stange EF, Lémann M, et al. European evidence-based consensus on the management of ulcerative colitis: current management. J Crohns Colitis 2008;2:24-62.
-
(2008)
J Crohns Colitis
, vol.2
, pp. 24-62
-
-
Travis, S.P.1
Stange, E.F.2
Lémann, M.3
-
5
-
-
79751472562
-
The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organization: When to start, when to stop, which drug to choose, and how to predict response?
-
quiz 213
-
D'Haens GR, Panaccione R, Higgins PDR, et al. The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response? Am J Gastroenterol 2011;106:199-212; quiz 213.
-
(2011)
Am J Gastroenterol
, vol.106
, pp. 199-212
-
-
D'Haens, G.R.1
Panaccione, R.2
Higgins, P.D.R.3
-
6
-
-
77950843556
-
Anti-TNF and Crohn's disease: When should we stop?
-
Louis E, Belaiche J, Reenaers C. Anti-TNF and Crohn's disease: when should we stop? Curr Drug Targets 2010;11:148-51.
-
(2010)
Curr Drug Targets
, vol.11
, pp. 148-151
-
-
Louis, E.1
Belaiche, J.2
Reenaers, C.3
-
7
-
-
79952795096
-
Review article: IFX for Crohn's disease treatment - Shifting therapeutic strategies after 10 years of clinical experience
-
Danese S, Colombel JF, Reinisch W, et al. Review article: IFX for Crohn's disease treatment - shifting therapeutic strategies after 10 years of clinical experience. Aliment Pharmacol Ther 2011;33:857-69.
-
(2011)
Aliment Pharmacol Ther
, vol.33
, pp. 857-869
-
-
Danese, S.1
Colombel, J.F.2
Reinisch, W.3
-
8
-
-
83555174451
-
Stopping immunomodulators and biologics in inflammatory bowel disease patients in remission
-
Clarke K, Regueiro M. Stopping immunomodulators and biologics in inflammatory bowel disease patients in remission. Inflamm Bowel Dis 2012;18:174-9.
-
(2012)
Inflamm Bowel Dis
, vol.18
, pp. 174-179
-
-
Clarke, K.1
Regueiro, M.2
-
9
-
-
79958095982
-
Severe infusion reactions to IFX: Aetiology, immunogenicity and risk factors in patients with inflammatory bowel disease
-
Steenholdt C, Svenson M, Bendtzen K, et al. Severe infusion reactions to IFX: aetiology, immunogenicity and risk factors in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2011;34:51-8.
-
(2011)
Aliment Pharmacol Ther
, vol.34
, pp. 51-58
-
-
Steenholdt, C.1
Svenson, M.2
Bendtzen, K.3
-
10
-
-
79959929224
-
Incidence of acute severe infusion reactions to IFX depends on definition used rather than assay: Authors' reply
-
Steenholdt C, Svenson M, Bendtzen K, et al. Incidence of acute severe infusion reactions to IFX depends on definition used rather than assay: authors' reply. Aliment Pharmacol Ther 2011;34:404-5.
-
(2011)
Aliment Pharmacol Ther
, vol.34
, pp. 404-405
-
-
Steenholdt, C.1
Svenson, M.2
Bendtzen, K.3
-
11
-
-
79953761841
-
Guidelines for the management of inflammatory bowel disease in adults
-
Mowat C, Cole A, Windsor A, et al. Guidelines for the management of inflammatory bowel disease in adults. Gut 2011;60:571-607.
-
(2011)
Gut
, vol.60
, pp. 571-607
-
-
Mowat, C.1
Cole, A.2
Windsor, A.3
-
12
-
-
83955162272
-
Maintenance of remission among patients with Crohn's disease on antimetabolite therapy after IFX therapy is stopped
-
quiz e31
-
Louis E, Mary JY, Vernier-Massouille G, et al. Maintenance of remission among patients with Crohn's disease on antimetabolite therapy after IFX therapy is stopped. Gastroenterology 2012;142:63-70.e5; quiz e31.
-
(2012)
Gastroenterology
, vol.142
, pp. 63-70.e5
-
-
Louis, E.1
Mary, J.Y.2
Vernier-Massouille, G.3
-
13
-
-
84872689289
-
Predictors of relapse in patients with Crohn's disease in remission after 1 year of biological therapy
-
Molnár T, Lakatos PL, Farkas K, et al. Predictors of relapse in patients with Crohn's disease in remission after 1 year of biological therapy. Aliment Pharmacol Ther 2013;37:225-33.
-
(2013)
Aliment Pharmacol Ther
, vol.37
, pp. 225-233
-
-
Molnár, T.1
Lakatos, P.L.2
Farkas, K.3
-
14
-
-
84859590148
-
Outcome after discontinuation of IFX in patients with inflammatory bowel disease in clinical remission: An observational Danish single center study
-
Steenholdt C, Molazahi A, Ainsworth MA, et al. Outcome after discontinuation of IFX in patients with inflammatory bowel disease in clinical remission: an observational Danish single center study. Scand J Gastroenterol 2012;47:518-27.
-
(2012)
Scand J Gastroenterol
, vol.47
, pp. 518-527
-
-
Steenholdt, C.1
Molazahi, A.2
Ainsworth, M.A.3
-
15
-
-
36549071038
-
Clinical course in Crohn's disease: Results of a Norwegian population-based ten-year follow-up study
-
Solberg IC, Vatn MH, Høie O, et al. Clinical course in Crohn's disease: results of a Norwegian population-based ten-year follow-up study. Clin Gastroenterol Hepatol 2007;5:1430-8.
-
(2007)
Clin Gastroenterol Hepatol
, vol.5
, pp. 1430-1438
-
-
Solberg, I.C.1
Vatn, M.H.2
Høie, O.3
-
16
-
-
0037434552
-
Influence of immunogenicity on the long-term efficacy of IFX in Crohn's disease
-
Baert F, Noman M, Vermeire S, et al. Influence of immunogenicity on the long-term efficacy of IFX in Crohn's disease. N Engl J Med 2003;348:601-8.
-
(2003)
N Engl J Med
, vol.348
, pp. 601-608
-
-
Baert, F.1
Noman, M.2
Vermeire, S.3
-
18
-
-
62049083383
-
Loss of response and requirement of IFX dose intensification in Crohn's disease: A review
-
Gisbert JP, Panés J. Loss of response and requirement of IFX dose intensification in Crohn's disease: a review. Am J Gastroenterol 2009;104:760-7.
-
(2009)
Am J Gastroenterol
, vol.104
, pp. 760-767
-
-
Gisbert, J.P.1
Panés, J.2
-
19
-
-
79751477764
-
Cut-off levels and diagnostic accuracy of IFX trough levels and anti-IFX antibodies in Crohn's disease
-
Steenholdt C, Bendtzen K, Brynskov J, et al. Cut-off levels and diagnostic accuracy of IFX trough levels and anti-IFX antibodies in Crohn's disease. Scand J Gastroenterol 2011;46:310-18.
-
(2011)
Scand J Gastroenterol
, vol.46
, pp. 310-318
-
-
Steenholdt, C.1
Bendtzen, K.2
Brynskov, J.3
-
20
-
-
70350645060
-
Individual medicine in inflammatory bowel disease: Monitoring bioavailability, pharmacokinetics and immunogenicity of anti-tumour necrosis factor-alpha antibodies
-
Bendtzen K, Ainsworth M, Steenholdt C, et al. Individual medicine in inflammatory bowel disease: monitoring bioavailability, pharmacokinetics and immunogenicity of anti-tumour necrosis factor-alpha antibodies. Scand J Gastroenterol 2009;44:774-81.
-
(2009)
Scand J Gastroenterol
, vol.44
, pp. 774-781
-
-
Bendtzen, K.1
Ainsworth, M.2
Steenholdt, C.3
-
22
-
-
84864655177
-
Clinical implications of variations in anti-IFX antibody levels in patients with inflammatory bowel disease
-
Steenholdt C, Al-Khalaf M, Brynskov J, et al. Clinical implications of variations in anti-IFX antibody levels in patients with inflammatory bowel disease. Inflamm Bowel Dis 2012;18:2209-17.
-
(2012)
Inflamm Bowel Dis
, vol.18
, pp. 2209-2217
-
-
Steenholdt, C.1
Al-Khalaf, M.2
Brynskov, J.3
-
23
-
-
0026748231
-
Incidence and prevalence of Crohn's disease in the county of Copenhagen, 1962-87: A sixfold increase in incidence
-
Munkholm P, Langholz E, Nielsen OH, et al. Incidence and prevalence of Crohn's disease in the county of Copenhagen, 1962-87: a sixfold increase in incidence. Scand J Gastroenterol 1992;27:609-14.
-
(1992)
Scand J Gastroenterol
, vol.27
, pp. 609-614
-
-
Munkholm, P.1
Langholz, E.2
Nielsen, O.H.3
-
24
-
-
78649583974
-
Endoscopic evaluation of Crohn's disease activity: Comparison of the CDEIS and the SES-CD
-
Internet
-
Sipponen T, Nuutinen H, Turunen U, et al. Endoscopic evaluation of Crohn's disease activity: Comparison of the CDEIS and the SES-CD [Internet]. Inflamm Bowel Dis 2010;16:2131-6.
-
(2010)
Inflamm Bowel Dis
, vol.16
, pp. 2131-2136
-
-
Sipponen, T.1
Nuutinen, H.2
Turunen, U.3
-
25
-
-
4744375545
-
Development and validation of a new, simplified endoscopic activity score for Crohn's disease: The SES-CD
-
Daperno M, D'Haens G, Van Assche G, et al. Development and validation of a new, simplified endoscopic activity score for Crohn's disease: the SES-CD. Gastrointest Endosc 2004;60:505-12.
-
(2004)
Gastrointest Endosc
, vol.60
, pp. 505-512
-
-
Daperno, M.1
D'Haens, G.2
Van Assche, G.3
-
26
-
-
84862815614
-
MR enterography correlates highly with colonoscopy and histology for both distal ileal and colonic Crohn's disease in 310 patients
-
Grand DJ, Kampalath V, Harris A, et al. MR enterography correlates highly with colonoscopy and histology for both distal ileal and colonic Crohn's disease in 310 patients. Eur J Radiol 2012;81:e763-9.
-
(2012)
Eur J Radiol
, vol.81
, pp. e763-e769
-
-
Grand, D.J.1
Kampalath, V.2
Harris, A.3
-
27
-
-
77950116998
-
MR enterographic manifestations of small bowel Crohn disease
-
Tolan DJ, Greenhalgh R, Zealley IA, et al. MR enterographic manifestations of small bowel Crohn disease. Radiographics 2010;30:367-84.
-
(2010)
Radiographics
, vol.30
, pp. 367-384
-
-
Tolan, D.J.1
Greenhalgh, R.2
Zealley, I.A.3
-
28
-
-
0017227303
-
Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study
-
Best WR, Becktel JM, Singleton JW, et al. Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. Gastroenterology 1976;70:439-44.
-
(1976)
Gastroenterology
, vol.70
, pp. 439-444
-
-
Best, W.R.1
Becktel, J.M.2
Singleton, J.W.3
-
29
-
-
41549139577
-
Validity, reliability, and responsiveness of the work productivity and activity impairment questionnaire in Crohn's disease
-
Reilly MC, Gerlier L, Brabant Y, et al. Validity, reliability, and responsiveness of the work productivity and activity impairment questionnaire in Crohn's disease. Clin Ther 2008;30:393-404.
-
(2008)
Clin Ther
, vol.30
, pp. 393-404
-
-
Reilly, M.C.1
Gerlier, L.2
Brabant, Y.3
-
30
-
-
0029775580
-
The Short Inflammatory Bowel Disease Questionnaire: A quality of life instrument for community physicians managing inflammatory bowel disease
-
CCRPT Investigators. Canadian Crohn's Relapse Prevention Trial
-
Irvine EJ, Zhou Q, Thompson AK. The Short Inflammatory Bowel Disease Questionnaire: a quality of life instrument for community physicians managing inflammatory bowel disease. CCRPT Investigators. Canadian Crohn's Relapse Prevention Trial. Am J Gastroenterol 1996;91:1571-8.
-
(1996)
Am J Gastroenterol
, vol.91
, pp. 1571-1578
-
-
Irvine, E.J.1
Zhou, Q.2
Thompson, A.K.3
-
31
-
-
0024587749
-
A new measure of health status for clinical trials in inflammatory bowel disease
-
Guyatt G, Mitchell A, Irvine EJ, et al. A new measure of health status for clinical trials in inflammatory bowel disease. Gastroenterology 1989;96:804-10.
-
(1989)
Gastroenterology
, vol.96
, pp. 804-810
-
-
Guyatt, G.1
Mitchell, A.2
Irvine, E.J.3
-
32
-
-
84880570843
-
Comparison of techniques for monitoring IFX bioavailability and immunogenicity in Crohn's disease
-
Steenholdt C. Comparison of techniques for monitoring IFX bioavailability and immunogenicity in Crohn's disease. Ther Drug Monit 2013;35:530-8.
-
(2013)
Ther Drug Monit
, vol.35
, pp. 530-538
-
-
Steenholdt, C.1
-
33
-
-
80054859408
-
Reporter gene assay for the quantification of the activity and neutralizing antibody response to TNFα antagonists
-
Lallemand C, Kavrochorianou N, Steenholdt C, et al. Reporter gene assay for the quantification of the activity and neutralizing antibody response to TNFα antagonists. J Immunol Methods 2011;373:229-39.
-
(2011)
J Immunol Methods
, vol.373
, pp. 229-239
-
-
Lallemand, C.1
Kavrochorianou, N.2
Steenholdt, C.3
-
34
-
-
44649187924
-
Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: Meta-analysis of placebo-controlled trials."
-
Peyrin-Biroulet L, Deltenre P, de Suray N, et al. Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: meta-analysis of placebo-controlled trials." Clin Gastroenterol Hepatol 2008;6:644-53.
-
(2008)
Clin Gastroenterol Hepatol
, vol.6
, pp. 644-653
-
-
Peyrin-Biroulet, L.1
Deltenre, P.2
De Suray, N.3
-
35
-
-
33846592386
-
Hepatosplenic T cell lymphoma associated with IFX Use in young patients treated for inflammatory bowel disease
-
Mackey AC, Green L, Liang LC, et al. Hepatosplenic T cell lymphoma associated with IFX Use in young patients treated for inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2007;44:265-7.
-
(2007)
J Pediatr Gastroenterol Nutr
, vol.44
, pp. 265-267
-
-
Mackey, A.C.1
Green, L.2
Liang, L.C.3
-
36
-
-
72949116165
-
A network meta-analysis of randomized controlled trials of biologics for rheumatoid arthritis: A Cochrane overview
-
Singh JA, Christensen R, Wells GA, et al. A network meta-analysis of randomized controlled trials of biologics for rheumatoid arthritis: a Cochrane overview. CMAJ 2009;181:787-96.
-
(2009)
CMAJ
, vol.181
, pp. 787-796
-
-
Singh, J.A.1
Christensen, R.2
Wells, G.A.3
-
37
-
-
79955844276
-
2010 Update of the international ASAS recommendations for the use of anti-TNF agents in patients with axial spondyloarthritis
-
van der Heijde D, Sieper J, Maksymowych WP, et al. 2010 Update of the international ASAS recommendations for the use of anti-TNF agents in patients with axial spondyloarthritis. Ann Rheum Dis 2011;70:905-8.
-
(2011)
Ann Rheum Dis
, vol.70
, pp. 905-908
-
-
Van Der Heijde, D.1
Sieper, J.2
Maksymowych, W.P.3
-
38
-
-
84870322518
-
Discontinuation of adalimumab treatment in rheumatoid arthritis patients after achieving low disease activity
-
Harigai M, Takeuchi T, Tanaka Y, et al. Discontinuation of adalimumab treatment in rheumatoid arthritis patients after achieving low disease activity. Mod Rheumatol 2012;22:814-22.
-
(2012)
Mod Rheumatol
, vol.22
, pp. 814-822
-
-
Harigai, M.1
Takeuchi, T.2
Tanaka, Y.3
|